摘要
目的对照评估二甲双胍与瑞格列奈治疗糖尿病的应用效果。方法选择2014年5月~2015年5月我院收治的270例2型糖尿病患者作为研究对象,根据数字随机法把270例患者分成A组、B组和C组,其中A组给予二甲双胍治疗,B组给予瑞格列奈治疗,C组给予二甲双胍联合瑞格列奈治疗,以7 d作为1个月作为1个疗程,经过2个疗程治疗后,对比三组患者临床治疗效果与血糖指标变化情况。结果 C组治疗效果高于A组和B组,C组患者血糖改善情况优于A组和B组,对比差异有统计学意义（P〈0.05）。结论应用二甲双胍联合瑞格列奈治疗糖尿病疗效优于单独给药,而且疗效理想,患者临床不良反应较小,可以提高患者的治疗依从性,更好的控制血糖。
Objective To evaluate the application effect of diabetes with metformin and repaglinide in controlled trial. Methods 270 cases of type 2 diabetes choose from May 2014 to May 2015 in our hospital as objects of study, according to random number method,the 270 cases of patients were randomly divided into group A, group B and group C, where A group received metformin, B repaglinide treatment group were given, group C repaglinide administered metformin therapy to 7 d as a month as a course of treatment, after two courses of treatment, compared to 3 groups of patients with clinical effect changes in glycemic index. Results Group C treatment significantly higher than group A and group B, group C improvement of blood glucose than patients in group A and group B, contrast significant difference（P〈0.05）. Conclusion Clinical application diabetes treatment was superior to metformin repaglinide administered alone, but the desired effect, a small clinical adverse reactions, can improve patient compliance and better control of blood sugar, should be widely applied.
出处
《中国卫生标准管理》
2015年第33期118-119,共2页
China Health Standard Management
